Source: Annual Congress 2010 - Pulmonary vascular involvement in COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
N. Voelkel (Richmond, United States of America). Vasoactive and growth factors in pulmonary emphysema. Annual Congress 2010 - Pulmonary vascular involvement in COPD

Member's Comments

No comment yet.

Related content which might interest you: Inhalation of vasoactive intestinal peptide in pulmonary hypertension Source: Annual Congress 2008 - Medical treatment of pulmonary hypertension Year: 2008 Expression vasoactive intestinal peptide and related receptors in overcirculation-induced pulmonary hypertension in piglets Source: Eur Respir J 2006; 28: Suppl. 50, 659s Year: 2006 Vasoactive intestinal peptide receptors in the airways of smokers with chronic bronchitis Source: Eur Respir J 2004; 24: 958-963 Year: 2004 Growth factors and interleukin-6 across the lung circulation in pulmonary hypertension Source: Eur Respir J 2009; 34: 662 Year: 2009 Vasoactive intestinal peptide-receptor regulation in monocytes derived from COPD patients Source: Annual Congress 2007 - Cell biology of asthma and COPD Year: 2007 Inhalation of vasoactive intestinal peptide in pulmonary hypertension Source: Eur Respir J 2008; 32: 1289-1294 Year: 2008 Effects of different pacing modes on vasoactive intestinal peptide levels in pacemaker patients with chronic obstructive pulmonary disease Source: Eur Respir J 2001; 18: Suppl. 33, 58s Year: 2001 Pulmonary vascular remodelling in pulmonary disease Source: Annual Congress 2011 - The burden of pulmonary hypertension in respiratory disease Year: 2011 Vasoactive intestinal peptide receptor 2 (VIPR2) in central airways of smokers Source: Eur Respir J 2002; 20: Suppl. 38, 88s Year: 2002 Pulmonary arterial hypertension (PAH) in mice lacking the vasoactive intestinal polypeptide (VIP) gene: morphometric evidence for vascular remodeling Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals Year: 2006 Vasoactive intestinal peptide (VIP) markedly attenuates pulmonary hypertension in fawn-hooded rats Source: Annual Congress 2005 - Pulmonary hypertension: pathophysiology Year: 2005 Vasoactive intestinal peptide (VIP) for treatment of COPD: improvement in spiroergometry and 6 minute walking distance Source: Eur Respir J 2006; 28: Suppl. 50, 430s Year: 2006 Insulin-like growth factor-1 contributes to the pulmonary artery smooth muscle cell proliferation in pulmonary arterial hypertension Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014 Circulating vasoactive intestinal peptide for diagnosis of exacerbation of COPD Source: International Congress 2015 – Monitoring and phenotyping COPD Year: 2015 Upregulation of basic fibroblast growth factor in smokers with chronic bronchitis Source: Eur Respir J 2006; 27: 957-963 Year: 2006 Vascular endothelial growth factor (VEGF) and airway inflammation in COPD. Correlation with pulmonary function Source: Eur Respir J 2006; 28: Suppl. 50, 653s Year: 2006 Hypoxia inducible factor-1? in human emphysema lung tissue Source: Eur Respir J 2011; 37: 775-783 Year: 2011 Inhaled vasoactive intestinal peptide exerts immune-regulatory effects in patients with sarcoidosis Source: Annual Congress 2009 - From genetics to clinics in diffuse parenchymal lung diseases Year: 2009 Inhaled vasoactive intestinal peptide (VIP) improves pulmonary gas exchange in acute respiratory distress syndrome (ARDS) - a case report Source: Eur Respir J 2003; 22: Suppl. 45, 70s Year: 2003 Growth factors in chronic obstructive pulmonary disease Source: Eur Respir J 2004; 24: Suppl. 48, 320s Year: 2004